Gabev EE, Gabev EB, Beshkov D, Argirova R; International Conference on AIDS.
Int Conf AIDS. 1991 Jun 16-21; 7: 92 (abstract no. W.A.1003).
Institute of Parasitology, Bulgarian Academy of Sciences, Sofia, Bulgaria
OBJECTIVE: To evaluate the anti-HIV effect of encapsulated in freeze-thawed liposomes AZT plus PEBA (FTL/AZT/PEBA) versus FTL/AZT and AZT-free. METHODS: MT4 cells and HIV-1 from H9(HTLV-IIIB) were used. FTL/AZT/PEBA, FTL/AZT, and AZT-free (AZT always at 4.5 microM/1) were added to the cells once after virus inoculation. Toxicity and HIV replication were monitored by MTT assay and p24 Ag ELISA once weekly for 21 days. RESULTS: No toxicity of all three preparations was observed. On day 7 all three preparations showed well-expressed but similar anti-HIV effect. On day 14 FTL/AZT was at least two times more effective than AZT-free, while for FTL/AZT/PEBA this anti-HIV effect was more than 60 times higher. On day 21 FTL/AZT/PEBA and FTL/AZT still show anti-HIV effect while AZT-free was no more active. CONCLUSIONS: Liposome encapsulation enhances and prolongs in vitro anti-HIV effect of AZT especially in combination with PEBA. This approach is perspective for dose diminishing and extension of application for toxic drugs, such as AZT. Liposome encapsulation also allows combination of synergically acting agents as evident in this study for AZT plus PEBA.
Publication Types:
Keywords:
- Acquired Immunodeficiency Syndrome
- Anti-HIV Agents
- HIV
- HIV Core Protein p24
- HIV Infections
- HIV Seropositivity
- HIV-1
- In Vitro
- Liposomes
- Zidovudine
- immunology
- reverse transcriptase, Human immunodeficiency virus 1
Other ID:
UI: 102192194
From Meeting Abstracts